Company: TELO
Filing Date: 2025-11-10
Form Type: 10-Q
Source: 0001493152-25-021496
Chunk: 55

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-10
Form: 10-Q
Item: Item 8
Chunk 55
---
 total of 1,200,000 shares of our common stock, no par value, in block sales to institutional investors,
at an average price of $1.82 per share, (a premium to the prior day’s close), through our at-the-market equity offering facility.

●
On August 28, 2025, we announced new in vitro results that expand understanding of our lead drug candidate, Telomir-1. In studies conducted
by Eurofins Discovery, Telomir-1 was shown to potently inhibit UTX (KDM6A), an enzyme that acts like an “eraser” of chemical
tags on DNA packaging proteins. These tags, known as DNA methylation and histone marks, are part of the body’s system for deciding
which genes are turned on or off - much like switches on a circuit board.

●
On September 9, 2025 we reported new preclinical cancer data showing that Telomir-1 reverses DNA methylation of CDKN2A, a master tumor
suppressor gene silenced in many aggressive cancers.

●
On September 18, 2025, we reported new in vitro pharmacology results demonstrating that Telomir-1 potently inhibits three members of
the KDM5 histone demethylase family. Histone demethylases are upstream gene regulators that cancers exploit to silence tumor suppressors
and activate inflammatory programs. Blocking these enzymes has long been viewed as scientifically important but clinically challenging,
with KDM5 often described as challenging for development

●
On October 7, 2025, we announced new preclinical results showing that our investigational therapy Telomir-1 reactivated two of the body’s
most important tumor suppressor genes, MASPIN (“tumor suppressor shield”) and RASSF1A (“guardian gene”; also
called SERPINB5), through DNA methylation reset in prostate cancer models. By restoring the activity of these genes, Telomir-1 may help
prevent cancer spread and improve chemotherapy response

●
On October 9, 2025, we announced new findings demonstrating that Telomir-1 significantly decreases the viability of aggressive triple-negative
breast cancer (TNBC) cells - a highly invasive form of breast cancer that lacks hormone and HER2 receptors, offers limited treatment
options, and carries one of the poorest survival rates among breast cancer subtypes.

●
On October 9, 2025, we sold a total of